Spironolactone in cardiovascular disease: an expanding universe? - Wikidata - wikimedia - TriplyDB

Spironolactone in cardiovascular disease: an expanding universe?

Spironolactone in cardiovascular disease: an expanding universe?

http://www.wikidata.org/entity/Q42364781

about

Spironolactone in cardiovascular disease: an expanding universe?

http://www.wikidata.org/entity/Q42364781

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Spironolactone in cardiovascular disease: an expanding universe?

@en

Spironolactone in cardiovascular disease: an expanding universe?

@nl

type

label

Spironolactone in cardiovascular disease: an expanding universe?

@en

Spironolactone in cardiovascular disease: an expanding universe?

@nl

prefLabel

Spironolactone in cardiovascular disease: an expanding universe?

@en

Spironolactone in cardiovascular disease: an expanding universe?

@nl

P1433

Q42364781-C185BB16-CC0A-4714-8241-538227DEB30E

P1476

Q42364781-16ADDD58-5AAD-4583-942A-87658A28D64E

P2093

Q42364781-39F9730D-2FB2-4240-BC1B-96A905F083DA

P2860

Q42364781-01852446-9355-4F25-8175-C3C934372E72

Q42364781-02399174-1B36-4DBF-8A9E-DD6AF3029E18

Q42364781-0FFF3766-BD1A-4720-B1E4-632E2AD5C3B9

Q42364781-14A22073-22BC-4598-AB10-2C5035B20E5F

Q42364781-1E4E51A7-DE65-491B-8C5B-B0865A1F040A

Q42364781-2BCEC30B-6AAB-437F-8406-03E36A25FD2B

Q42364781-308BCDAF-CF72-47F7-818C-CEB795B49240

Q42364781-3098D742-BE40-442A-B388-03C87CE539B5

Q42364781-33D103DB-32EA-4904-A0A7-D8C1E4BD4571

Q42364781-3BF2F259-3A8C-46BA-ADE3-99FBB3DC6E7A

P304

Q42364781-43F100E6-73CD-4BB6-9A7F-FA2A97E34113

P31

Q42364781-DCFFCBC7-BAAC-4BB8-A52E-E2BA234C4488

P356

Q42364781-A5E1C3A1-CE34-4833-976D-69D4A1EB2E2F

P478

Q42364781-FADF6C09-6BDB-48B2-B7A4-DE53297D0CF8

P577

Q42364781-98DD3011-B7EA-476C-B29B-D9AB2B9B9CF2

P698

Q42364781-4329DA7C-86FB-4665-A5CD-C11288B73C32

P932

Q42364781-81ECB88C-157B-48B9-B9F4-CC99539933B6

P356

F1000RESEARCH.11887.1

P1433

P1476

Spironolactone in cardiovascular disease: an expanding universe?

@en

P2093

John W Funder

http://www.w3.org/2001/XMLSchema#string

P2860

A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Spironolactone for heart failure with preserved ejection fraction.

Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments.

Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.

Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia

Emerging cardiovascular indications of mineralocorticoid receptor antagonists.

P304

1738

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/F1000RESEARCH.11887.1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29034087

http://www.w3.org/2001/XMLSchema#string

P932

5615771

http://www.w3.org/2001/XMLSchema#string